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Background: Low functional ovarian reserve (LFOR) has been associated with hypoandrogenemia and increased
embryo aneuploidy, while androgen supplementation has been reported to improve aneuploidy rates. We,
therefore, assessed whether in infertile women undergoing in vitro fertilization (IVF) androgen concentrations are
associated with aneuploidy rates.
Methods: This study was performed in 2 academically affiliated fertility centers in New York City and an academically
affiliated steroid chemistry laboratory in Utah. Androgen concentrations were measured in blinded fashion from 84
infertile women (age 40.3 +/− 2.4 years) at New York University (NYU), using a validated LC-MS/MS method, in
cryopreserved serum samples of patients who had undergone IVF with concomitant preimplantation genetic
screening (PGS), utilizing a 24-chromosome platform. The Center for Human Reproduction (CHR) provided plasma
samples of 100 historical controls (ages 38.6+/−5.0 years) undergoing IVF without PGS. Statistical comparisons were
made of androgen concentrations, and of associations between androgen concentrations and embryo aneuploidy.
Results: Women undergoing IVF + PGS at NYU revealed no association between embryo aneuploidy and androgen
concentrations but demonstrated significantly lower androgen concentrations than the 100 control patients from CHR,
Conclusions: Though this study revealed no association between androgen levels and embryo ploidy, the extremely
low androgen levels in the NYU study group raise the possibility of a threshold effect below which testosterone no
longer affects aneuploidy. Before an androgen effect on embryo ploidy can be completely ruled out, a patient population
with more normal androgen levels has to be investigated.
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Aneuploidy represents a frequent phenomenon in human
reproduction, and is to a large degree oocyte-dependent
[1,2]. Though even young women at peak fertility produce
a large number of aneuploid embryos, rates of aneuploidy
increase with advancing female age [3]. Recent animal [4]
and human data [5] suggest that loss of functional ovarian
reserve (FOR), in itself, may be associated with increased
embryo aneuploidy. Whether increases in aneuploidy are
exclusively age-related, independently also associated with
premature loss of FOR in association with premature
ovarian aging (POA) or with both has, however, remained* Correspondence: ngleicher@thechr.com
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unless otherwise stated.controversial. Some studies have suggested that POA, if
adjusted for age, does not predispose to higher aneuploidy
rates [6].
What causes the high rate of aneuploidy in human oo-
cytes and embryos is so far only partially understood [1].
Androgen supplementation has, however, been suggested
to reduce aneuploidy rates [7]. This observation is further
supported by significant decreases in miscarriage rates with
androgen supplementation, especially in older women [8].
Whether caused by physiologic female aging or POA, low
functional ovarian reserve (LFOR) has, almost universally,
also been associated with relative hypoandrogenemia [9].
These associations raise the interesting question as to
whether androgen levels may be associated with aneuploidy
risk? Here presented is a collaborative study between twol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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attempting to answer this question.
Methods
The Institutional Review Boards of New York University
(NYU) School of Medicine and the Center for Human
Reproduction – New York approved this study.
Study population
Women were identified who presented to NYU between
2013 and 2014 for IVF with 24-chromosome pre-
implantation genetic screening (PGS). Exclusion criteria
were: hormonal suppression prior to cycle start [oral
contraceptives, gonadotropin releasing hormone agonist
(GnRH) down-regulation or GnRH antagonist], uses of
donor oocytes, or if cryopreserved serum was unavailable.
Once the androgen concentrations of the study group
were recognized to be low, the question arose whether
these concentrations were typical of infertile women of
corresponding age. To answer this question, we randomly
selected plasma samples from 100 infertile women as con-
trols, who had undergone IVF at the Center for Human
Reproduction (CHR) during the same time as the NYU
study group.
Study parameters in IVF cycles
Cycle parameters analyzed included patient age at the
time of oocyte retrieval, day 2 follicle stimulating hor-
mone (FSH) and estradiol (E2) levels, anti-Müllerian
hormone (AMH), total units of gonadotropin [FSH and
human menopausal gonadotropins (hMG)], number of
days to human chorionic gonadotropin (hCG) trigger, E2
level on the day of ovulation trigger, numbers of oocytes
and metaphase-II (M-II) oocytes retrieved, number of
two pronuclear (2PN) zygotes, number of euploid and
aneuploid and euploid blastocysts, and embryos with no
diagnosis. A euploid-index was calculated by dividing
the total number of euploid embryos by the total number
of embryos biopsied (euploid + aneuploid + no diagnosis).
Serum samples were assayed for dehydroepiandrosterone
(DHEA), Androstenedion and total testosterone.
Ovarian stimulation
Before initiation of treatment, menstrual day 2 or 3
serum E2 and FSH levels were assessed. Patients with
acceptable parameters (E2 < 75 and FSH <13.5) were
stimulated using injectable gonadotropins (Follitropin
beta, Schering Plough, NJ; Serono Pharmaceuticals,
Rockland, MA; Menotropins, Ferring Pharmaceuticals,
Parsippany, NJ), with LH suppression achieved using a
GnRH antagonist (ganirelix acetate, Organon; cetrorelix,
Serono). Ovulation was triggered when ≥ 2 follicles
reached ≥ 17 mm in diameter, and ultrasound-guidedtrans-vaginal oocyte retrieval was performed 34–36
hours later.
Laboratory assays
Preimplantation genetic diagnosis (PGS)
Laser-assisted breaching of the zona pellucida was
performed on day 3 (Cronus, Research Instruments,
UK). Embryos were assessed on days 5 and 6, and fully
differentiated blastocysts meeting criteria underwent
trophectoderm biopsy. The trophectoderm cells ex-
truding from the expanded blastocyst were gently
pulled using suction, and laser was used to remove
cells at cell junctions without disrupting the inner cell
mass. Biopsied trophectoderm cells were loaded into
PCR tubes and sent to the reference laboratory for 24-
chromosome analysis using array comparative genomic
hybridization (aCGH) as previously described [10,11].
Following biopsy, blastocysts were vitrified to be re-
placed in subsequent frozen cycles.
Androgen assays
Plasma samples of IVF patients were stored at −80°C at
NYU since cycle start. The samples were de-identified
and shipped on dry ice to the ARUP Institute (ARUP In-
stitute Laboratories, Salt Lake City, Utah), where they
were analyzed using a validated liquid chromatography
tandem mass spectrometry method (LC-MS/MS) for de-
hydroepiandrosterone (DHEA), Androstenedion, as well
as total testosterone [12].
Androgen concentrations of the CHR control group
were also assessed using LC-MS/MS, though at a com-
mercial laboratory (LabCorp, Burlington, North Carolina).
Two samples from each patient were analyzed, a baseline
sample obtained at initial presentation to the center and a
sample at IVF cycle start after on average 6–8 weeks of
supplementation with DHEA, 25 mg TID (Fertinatal®,
Fertility Nutraceuticals, LLC, New York, N.Y.) [13].
Five samples were investigated in both laboratories
(Utah and Bulington). In all five samples inter-assay vari-
ability between the laboratories was <5%.
Reagents and standards
Standards of testosterone, Androstenedion and DHEA,
were purchased from Cerilliant (Austin, TX); the internal
standards were deuterium labeled analogs of the steroids,
d3-testosterone (Sigma, St Louis, MO), d7-androstene-
dione (Ceriliant) and d5-DHEA (CDN Isotopes, Quebec,
Canada). All other chemicals were of the highest purity
commercially available.
Liquid chromatography tandem mass spectrometry
Plasma samples were analyzed for DHEA, Androstenedion
and testosterone using liquid chromatography tandem
mass spectrometry (LC-MS/MS) as previously described
Table 1 Patient characteristics in NYU study patients
n Mean SD or 95% CI
Age (years) 84 40.30 2.44
Day-2 FSH (IU/mL) 84 6.64 2.37
Day-2 E2 (pg/mL) 84 43.10* 38.82 - 47.77*
AMH (ng/mL) 69 1.77* 1.47 - 2.13*
Total gonanadtropins (IU) 83 4,098 1380
FSH (IU) 83 2,646 1138
HMG (IU) 83 1,451 889
Days to hCG trigger 83 9.55 1.59
E2 on day of trigger (pg/mL) 83 2282* 2066 - 2522*
Number of oocytes 84 13.35* 11.97 - 14.88*
Number of MII oocytes 84 11.85 6.13
2PN oocytes 84 7.76* 6.84 - 8.80*
DHEA (ng/dL) 84 294.7* 257.5 – 337.4*
Androstenedione (ng/dL) 84 60.1* 55.8 – 64.6*
Total testosterone (ng/dL) 84 16.7* 15.4 – 18.1*
Number of euploid embryos 84 1.51 1.81
Number of aneuploid embryos 84 3.62 2.93
Embryos with no diagnosis 84 0.31 1.01
Ploidy Index 84 0.29 0.29
*Denotes P<0.05.
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vatized with hydroxylamine to form oxime derivatives,
and analyzed on a triple quadruple mass spectrometer
(AB5500, AB Sciex, Foster City, CA), using an electrospray
ion source in positive ion mode. The HPLC system con-
sisted of series 1260 HPLC pumps (Agilent Technologies),
and an HTC PAL auto sampler (LEAP Technologies, NC),
equipped with a fast wash station.
The quadruples Q1 and Q3 were tuned to unit resolution
and the mass spectrometer conditions were optimized for
maximum signal intensity of each steroid. Two mass transi-
tions were monitored for each steroid and its internal
standard. Quantitative data analysis was performed using
software Analyst™ 1.5.2. Calibration curves were generated
using six calibrators; three quality control samples were
analyzed along with the samples.
Specificity of the analysis for each steroid in every
sample was evaluated by comparing concentrations de-
termined by using primary and secondary mass transi-
tions of each steroid and its internal standard [14]. Limit
of quantification (LOQ) was 0.01 ng/mL for testosterone
and Androstenedion, and 0.05 ng/ml for DHEA; Intra-
and inter-assay imprecisions were <8.0 percent.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statis-
tics for Windows, Version 21.0. (Armonk, NY: IBM Corp).
Continuous variables are presented as mean ± standard
deviation. If not normally distributed, the variables were
log transformed, and concentrations were presented as
mean and 95% confidence intervals (CI). Differences be-
tween continuous variables were, as appropriate, assessed
using ANOVA or ANCOVA.
We used cluster analysis to characterize the relation-
ships between the variables. A linear regression model was
used to assess the relationship of the number of euploid
embryos as a function of total of two-pronuclear (2PN)
embryos produced per patient and number of aneuploid
embryos. We then further used linear regression models
to evaluate how the concentration of DHEA, Androstene-
dion and total testosterone on cycle day-2 might affect this
model.
Results
The NYU study group was comprised of 84 women be-
tween ages 35 and 45 years (mean, 40.3 ± 2.4) who
underwent IVF with embryo culture to blastocyst stage
and trophectoderm biopsy. Patient characteristics are
presented in Table 1.
Functional ovarian reserve (FOR) assessment
Considering their ages, patients in this group demon-
strated almost excessively good functional ovarian reserve
for their age, defined by mean day-2 FSH of 6.6mIU/mL(95% CI, 6.1 – 7.2), mean estradiol of 43.1 pg/mL (95% CI,
38.8 – 47.8) and AMH of 1.8 ng/mL (95% CI, 1.5 - 2.1).
They also produced exceptionally good oocyte yields for
their ages, with a mean of 13.4 (95% CI, 12.0 - 14.9).Androgen concentrations
Cycle day-2 DHEA concentrations were widely distrib-
uted between 96.6 ng/dL and 865 ng/dL with [mean of
290.9 (95% CI, 261.2 to 324.0) ng/dL. Kushnir et al. re-
ported the normal range for DHEA in post menarchal
women to be 111–770 ng/dL with concentration declining
by approximately 15 percent per decade of life [10]. Only
three (3.6%) of women demonstrated DHEA below the
lower cut-off level of 111 ng/dL.
When the DHEA concentrations of the NYU patient
group, however, were compared to a randomly selected
historical control group of 100 infertile women of similar
age (Table 2), before and after supplementation with
DHEA, undergoing IVF at CHR, DHEA concentrations
of NYU patients were similar to CHR baseline levels
[294.7 ng/dL; (95% CI, 257.5 – 337.4); P = 0.23] but
highly significantly lower to CHR post-supplementation
levels [595.2 ng/dL (95% CI 539.2 – 651.1); P < 0.0001).
Cycle day-2 Androstenedion in NYU patients ranged
from 18.9 to 134 ng/dL [average 60.0 ng/dL ; (95% CI
56.0 – 67.1). Kushnir et al. reported normal levels of
Androstenedion in 323 post-menarchal women to be
Table 2 Comparison of androgen levels between NYU study and CHR control group
NYU-Baseline CHR –Baseline CHR post DHEA
(mean & 95% CI) (mean & 95% CI) (mean & 95% CI)
DHEA (ng/dL) 290.97 261.27 to 324.031 294.733 257.46 to 337.40 595.21 539.28 to 651.141
Androstenedion (ng/dL) 60.08 55.86 to 64.622 78.98 70.56 to 88.472 123.64 110.77 to 138.002
Testosterone (ng/dL) 16.67 15.35 to 18.112 21.77 19.60 to 24.182 32.14 28.62 to 36.092
1P < 0.0001; 2P < 0.001; The table demonstrates that DHEA levels were similar between NYU and CHR patients at treatment start but post-DHEA supplementation
CHR levels were significantly higher. Androstenedion and testosterone levels were even at baseline lower in NYU than CHR patients.
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approximately 5 percent per decade of life [10].
Among 100 randomly selected women at CHR pre-
DHEA supplementation day-2 Androstenedion concentra-
tions were significantly higher than those of NYU patients;
78.9 ng/dL (95% CI 70.5 - 88.5) (P < 0.001). After 6 weeks
of DHEA supplementation, Androstenedion concentrations
among CHR patients even rose further to 123.6 ng/dL
(95% CI, 110.7 - 138.0; P < 0.001).
Cycle day-2 total testosterone among NYU women was
16.7 ng/dL (95% CI, 15.4 - 18.1). Kushnir et al. reported
normal levels of total testosterone in 323 post-menarcheal
women to be 9 – 55 ng/dL , with concentrations not being
age-dependent throughout all reproductive ages [10].
Total testosterone levels appear more predictive of preg-
nancy than free testosterone levels [13].
Among 100 randomly selected women at CHR, baseline
total testosterone concentrations prior to DHEA supple-
mentation were significantly higher than those of NYU pa-
tients; 21.7 ng/dL (95% CI, 19.6 - 24,2; P < 0.001). After
DHEA supplementation total testosterone concentrations
among CHR patients further increased to 32.1 ng/dL (95%
CI, 28.6 - 36.1; P < 0.001).
Embryo ploidy
NYU patients produced an average of 1.51 ± 1.81 euploid
embryos and 3.63 ± 2.93 aneuploid embryos. We calcu-
lated a euploid-index by dividing the total number of eu-
ploid embryos by the total number of embryos biopsied
(euploid + aneuploid + no diagnosis). The mean value of
this index was 0.29 ± 0.29. We then performed a cluster
analysis, subdividing the sample into two groups, based
on their evidence of ovarian reserve (day-2 FSH, AMH
and units of gonadotropins used) and androgen profiles.
As expected based on earlier reports [9], the group
with lower ovarian reserve markers also had lower an-
drogen concentrations, while those with better ovarian
reserve had higher concentrations of androgens. The
euploid-index however remained unchanged for both
groups (Figure 1).
Further verifying our model using linear regression,
we confirmed that the number of euploid embryos per
patients was associated with the number of aneuploid
embryos per patient (Beta 0.185, t 1.7; P = 0.09), though
this relationship did not reach significance.Adding total number of fertilized oocytes to the model
made the relationship between euploid and aneuploid
embryos inverse (Beta −0.437, t −3.18, P = 0.002), and
allowed it to reach significance. This model reflects that,
after adjusting for numbers of oocytes biopsied, as euploid
embryo numbers increase, the number of aneuploid
embryos must decrease.
Adding further individual factors to the model allows
for the estimation of independent effects of each factor
on the model. Adding age to the model, thus, decreased
the significance of other factors as predictors of number
of euploid embryos because age is also highly correlated
with other factors included in the model.
Adding androgen concentrations, either individually or
combined, however, did not affect the model in any way,
confirming results in above described cluster analysis
that androgen concentrations, in ranges found in the
NYU dataset, were not associated with the number of
euploid embryos.
Discussion
We in this study attempted to investigate whether an-
drogen levels statistically related to embryo aneuploidy.
Obtained results were quite remarkable, though not as
expected: In contrast to expectations, multiple regression
models failed to demonstrate an association between con-
centrations of any of the investigated androgens and
embryo aneuploidy, whether adjusted for age or not.
This collaboration between two fertility centers in
New York City is the first systemic evaluation of associa-
tions of androgen concentrations with aneuploidy in an
unselected group of infertile women, undergoing IVF
and PGS at one New York City-based IVF center (NYU).
Patient selection was unbiased because collaborators
from the NYU Medical Centers at random selected
frozen-stored patient samples from a larger patient pool,
and investigators at CHR analyzed samples from a con-
trol group of age and by IVF cycle timing matched group
of infertility patients.
Androgen analyses in samples included in this study
were performed using validated mass spectrometry-based
methods of commercial reference laboratory methodology
as now recommended for scientific investigations [15],
and proven to provide the most specific measurements of
endogenous steroids [12,14]. All samples in this study
Figure 1 Cluster analysis for NYU study group. This figure demonstrates the cluster analysis of the NYU study group: Cluster 1; Cluster 2; The
white boxes represent distributions for the whole NYU study group of patients, while the horizontal lines define the characteristics of patients in
the two clusters. Cluster 1 presents women with relatively low gonadotropin dosage requirements of hMG and FSH. As expected, their AMH,
testosterone and Androstenedion levels are above median; yet, ploidy is exactly at median. Cluster 2 presents the opposite patient phenotype,
with required gonadotropin dosages being high, AMH and androgens low; yet, ploidy again remains at median. The cluster analysis, therefore,
demonstrates the expected associations between LFOR, high gonadotropin use and relative hypoandrogenism vs. normal FOR, with low
gonadotropin use and normal androgen levels.
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broken after results had been obtained.
Reported aneuploidy rates were then statistically as-
sociated with patients’ androgen concentrations, first in
multiple regression models and later, once regression
analyses did not demonstrate statistical associations, by
cluster analyses.
Cluster analysis (Figure 1), however, revealed fully
expected associations between gonadotropin dosage
utilized in IVF cycles and FOR, as defined by FSH and
AMH levels. Indeed, it also confirmed previously re-
ported observation of low androgen concentrations (in
this case total testosterone and Androstenedion) with
LFOR, as assessed by FSH and AMH [9]. Embryo
ploidy rates, however, remained steady at exactly me-
dian, whether women had lower or higher androgen
concentrations or lower or higher FOR by FSH and
AMH levels (Figure 1).
These unexpected findings, of course, demand explan-
ation. Only two possible explanations come to mind: In the
literature reported associations between LFOR and in-
creased aneuploidy [4,5] and of increased aneuploidy withlow androgen concentrations [7,8] are incorrect. While a
possibility, we consider this a less likely explanation.
This leaves as the only possible remaining explanation
that here-investigated NYU patients, after all, in a sub-
liminal way were selected. In this context it is important
to recall that while these patients were random infertility
patients, who underwent IVF and PGS at NYU, most of
them had previously failed IVF cycles without utilization
of PGS. They, thus, indeed represented a negatively se-
lected patient population with relative poor outcome
chances. Such patients usually exhibit LFOR, and with
this diagnosis they can be expected to demonstrate low
androgen concentrations [9].
Here investigated NYU patients, indeed, demonstrated
unusually low androgen levels, as this study demon-
strated. They, however, in a somewhat contradictory
presentation, also still demonstrated based on AMH,
FSH levels and oocyte yields surprisingly good FOR,
considering their rather ages (Table 1).
Such patients are currently under investigation at
CHR, with preliminary evidence suggesting that they
represent women with a lean polycystic ovary syndrome
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ages characteristically, however, presenting with severe
hypoandrogenemia; yet, as here observed in NYU pa-
tients, still surprisingly good FOR (reflected in AMH
and oocyte yield) considering their ages (Gleicher N,
Kushnir VA, Barad DH, unpublished observations).
Comparing DHEA, Androstenedion and testosterone
concentrations in these NYU patients with a similarly
selected group of infertility patients during the same
time period undergoing IVF at CHR, the NYU group
demonstrated significantly lower androgen concentra-
tions than the CHR group, a difference which even fur-
ther expanded after CHR patients were supplemented
with DHEA, currently at CHR a routine practice in
women with LFOR [16].
Published evidence of an association of androgen con-
centrations with embryo aneuploidy rates in two so far
published studies, however, comes exclusively from LFOR
patients supplemented with DHEA [7,8]. If one were to
assume that the results of these two studies are valid, the
only possible explanation for here reported absence of cor-
relation between androgen levels and embryo aneuploidy
would be that such a quantitative association only exists
above a certain minimum androgen levels, which DHEA-
supplemented women, of course, would always exceed.
This, of course, is presently only a hypothesis but a hy-
pothesis, which can be confirmed with relative ease by
repeating here reported study in an infertile population
with either normal androgen levels or in an infertile
population with very low androgen levels (like here in-
vestigated NYU patients) who, however, prior to IVF
cycle start receive androgen supplementation to raise
their testosterone levels into normal range.
Our here presented study, therefore, requires a signifi-
cant follow up effort before final statements about the
effects of androgen levels on embryo ploidy can be
made. What, however, can be stated quite unequivocally
based on this study is that in infertile women with severe
hypoandrogenemia androgen levels do not determine
aneuploidy.
Should further studies confirm our hypothesis of a
threshold level for androgens below which androgen ef-
fects on embryo ploidy are lost, definition of minimal
androgen concentrations (i.e., a certain threshold) above
which aneuploidy rates would decline in age-specific de-
grees would open potential new therapeutic options for
improving IVF pregnancy chances and reducing miscar-
riage risks. Consistent with such a prospect miscarriage
rates after DHEA supplementation start declining only
after approximately age 35 [8].
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